Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRIDEX CORPIRIX · Entity 7882 | Director | June 24, 2020 | June 26, 2020 |
| NATUS MEDICAL INCBABY · Entity 125256 | Director | June 06, 2018 | June 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRIDEX CORP
Report date June 24, 2020 · Filed June 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,348 |
Reported balance
After 2020-06-24 transaction · row 1
1 source rowRow 1 · 2020-06-24 · Grant · Acquired 18,348 · Balance 18,348 F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 24, 2021 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a member of the Issuer's Board of Directors through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 24, 2021 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a member of the Issuer's Board of Directors through such date.
NATUS MEDICAL INC
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 26,750 |
Reported balance
After 2018-06-06 transaction · row 1
1 source rowRow 1 · 2018-06-06 · Grant · Acquired 5,000 · Balance 26,750 |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-08 | Direct | 5,000 |
Reported balance
After 2018-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-06 · Exercise / conversion · Acquired 5,000 · Balance 5,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2020 Filed Jun 26, 2020 21:31 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantCommon Stock | 18,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039133 · doc4.xml · nonDerivative · entry 1 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,348 F1 · shares: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 24, 2021 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a member of the Issuer's Board of Directors through such date. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:28 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001209191-20-025347 · doc4.xml · derivative · entry 1 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-04-20 F1 · security: This option was granted pursuant to IRIDEX Corporation's 2008 Amended and Restated Equity Incentive Plan and is exempt pursuant to Rule16b-3. F2 · derivative.exercise_date: The shares are subject to vesting according to the following schedule: 1/48th of the total number of shares vest on May 20, 2020 and each month thereafter. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 17:12 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNonqualified Stock Option · Derivative | 5,000 | $10.69 Strike: $10.69 | $53,450.00 |
DisclosureSEC source: 0000878526-18-000098 · wf-form4_152849233061526.xml · derivative · entry 2 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2018-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 17:12 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 5,000 | $10.69 | $53,450.00 |
DisclosureSEC source: 0000878526-18-000098 · wf-form4_152849233061526.xml · nonDerivative · entry 1 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,750 Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 12:55 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 4,100 | $35.60 | $145,960.00 |
DisclosureSEC source: 0000878526-17-000053 · wf-form4_149823690013780.xml · nonDerivative · entry 1 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,750 F1 · shares: The shares vest in full on the first anniversary of the date of the award. Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:57 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNonqualified Stock Option · Derivative | 5,000 | $0.00 Strike: $16.38 | $0.00 |
DisclosureSEC source: 0000878526-17-000045 · wf-form4_149617781729607.xml · derivative · entry 3 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:57 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 5,000 | $32.68 | $163,400.00 |
DisclosureSEC source: 0000878526-17-000045 · wf-form4_149617781729607.xml · nonDerivative · entry 2 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,650 Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:57 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 5,000 | $16.38 | $81,900.00 |
DisclosureSEC source: 0000878526-17-000045 · wf-form4_149617781729607.xml · nonDerivative · entry 1 Engibous Doris · CIK 0001289618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.